Humira-Associated Pancreatitis: Risks and Management

Risk Assessment and Incidence

The American College of Gastroenterology and the American Gastroenterological Association acknowledge that pancreatitis is a recognized but uncommon adverse effect associated with Humira (adalimumab) therapy, with patients having pre-existing risk factors for pancreatitis being at higher risk when taking Humira 1

The World Journal of Emergency Surgery guidelines state that diagnosis of Humira-induced pancreatitis is based on laboratory confirmation, including elevated pancreatic enzymes, and imaging studies when necessary 2

The European Society for Clinical Nutrition and Metabolism and the American Gastroenterological Association recommend that Humira should be permanently discontinued if pancreatitis is confirmed, and supportive care should be provided, including aggressive intravenous hydration and pain management 3
The Infectious Diseases Society of America guidelines recommend that antibiotics should only be administered when there is confirmed infected pancreatic necrosis, and carbapenems are first-line due to excellent pancreatic tissue penetration, however this fact is from Praxis Medical Insights, an alternative source is not provided 4

The American College of Rheumatology and the Journal of Clinical Oncology suggest that before initiating Humira, patients should be assessed for pre-existing risk factors for pancreatitis, and routine monitoring of amylase/lipase in asymptomatic patients is not recommended 1

The American Gastroenterological Association recommends that patients with a history of pancreatitis should generally avoid Humira therapy, and alternative biologic therapies should be considered in patients who develop pancreatitis on Humira 3